274 related articles for article (PubMed ID: 31017664)
1. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
George TJ; Franke AJ; Chakravarthy AB; Das P; Dasari A; El-Rayes BF; Hong TS; Kinsella TJ; Landry JC; Lee JJ; Monjazeb AM; Jacobs SA; Raben D; Rahma OE; Williams TM; Wu C; Coleman CN; Vikram B; Ahmed MM
Cancer; 2019 Aug; 125(16):2732-2746. PubMed ID: 31017664
[TBL] [Abstract][Full Text] [Related]
2. Development of Novel Radiosensitizers through the National Cancer Institute's Small Business Innovation Research Program.
Zakeri K; Narayanan D; Prasanna PGS; Vikram B; Buchsbaum JC
Radiat Res; 2020 May; 193(5):425-434. PubMed ID: 32216707
[TBL] [Abstract][Full Text] [Related]
3. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
[TBL] [Abstract][Full Text] [Related]
4. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges.
Vatner R; James CD; Sathiaseelan V; Bondra KM; Kalapurakal JA; Houghton PJ
Pediatr Blood Cancer; 2021 May; 68 Suppl 2():e28439. PubMed ID: 32827353
[TBL] [Abstract][Full Text] [Related]
5. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
[TBL] [Abstract][Full Text] [Related]
6. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
7. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.
Lin SH; George TJ; Ben-Josef E; Bradley J; Choe KS; Edelman MJ; Guha C; Krishnan S; Lawrence TS; Le QT; Lu B; Mehta M; Peereboom D; Sarkaria J; Seong J; Wang D; Welliver MX; Coleman CN; Vikram B; Yoo S; Chung CH; ;
J Natl Cancer Inst; 2013 May; 105(10):686-93. PubMed ID: 23503600
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells.
Spagnoletti G; Li Bergolis V; Piscazzi A; Giannelli F; Condelli V; Sisinni L; Bove G; Storto G; Landriscina M
Tumour Biol; 2018 Apr; 40(4):1010428318770957. PubMed ID: 29663854
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer.
Jeong YK; Kim MS; Lee JY; Kim EH; Kim W; Ha H; Jeong JH
Tumori; 2013; 99(2):176-82. PubMed ID: 23748811
[TBL] [Abstract][Full Text] [Related]
10. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.
Takebe N; Ahmed MM; Vikram B; Bernhard EJ; Zwiebel J; Norman Coleman C; Kunos CA
Semin Radiat Oncol; 2016 Oct; 26(4):271-80. PubMed ID: 27619249
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Saelen MG; Ree AH; Kristian A; Fleten KG; Furre T; Hektoen HH; Flatmark K
Radiat Oncol; 2012 Sep; 7():165. PubMed ID: 23017053
[TBL] [Abstract][Full Text] [Related]
12. Evolving role of neoadjuvant therapy in rectal cancer.
Schrag D
Curr Treat Options Oncol; 2013 Sep; 14(3):350-64. PubMed ID: 23828092
[TBL] [Abstract][Full Text] [Related]
13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
14. Combination effect of cetuximab with radiation in colorectal cancer cells.
Shin HK; Kim MS; Lee JK; Lee SS; Ji YH; Kim JI; Jeong JH
Tumori; 2010; 96(5):713-20. PubMed ID: 21302618
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.
Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT
Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
Kabakov AE; Kudriavtsev VA; Makarova IuM
Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
[TBL] [Abstract][Full Text] [Related]
19. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Wirsdörfer F; de Leve S; Jendrossek V
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
[TBL] [Abstract][Full Text] [Related]
20. Basics to advances in nanotherapy of colorectal cancer.
Tiwari A; Saraf S; Jain A; Panda PK; Verma A; Jain SK
Drug Deliv Transl Res; 2020 Apr; 10(2):319-338. PubMed ID: 31701486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
